Figure 7.

Autoimmune insulitis is attenuated by intracellular delivery of a nuclear transport modifier (MTM). A, Immunofluorescent analysis of pancreas obtained from cyclophosphamide (Cy)‐synchronized non‐obese diabetes (NOD) mice treated with NTM (cSN50 peptide) or non–cell‐penetrating NTM (cN50 peptide as inactive control). Pancreas section was stained with anti‐CD3‐PE (red, T cells) or anti‐B220‐FITC (green, B cells). B, Short‐term intracellular delivery of NTM, cSN50, protects NOD mice from autoimmune diabetes for over 1 y. C, 52‐week‐old Cy‐synchronized NOD mice show no signs of insulitis after short‐term treatment with NTM (right) as compared to the 15‐week‐old NOD mice from the beginning of experiment (adapted from Moore et al, PLoS ONE, 2010)